medigraphic.com
ISSN 1025-0255 (Electronic)

2015, Number 4

<< Back Next >>

AMC 2015; 19 (4)

Results of Heberprot-P® in patients with diabetic foot ulcers

González RR, Cardentey GJ, Casanova MMC

Language: Spanish
References: 21
Page: 366-374
PDF size: 568.81 Kb.


ABSTRACT

Background: diabetic foot syndrome is one of the chronic complications that cause more morbidity and disability in diabetic patients nowadays. High amputation rates cause a significant degree of disability along with a high social and economic cost. It has been showed that the use of Heberprot-p® stimulates granulation tissue formation in the ulcer bed and the closing by second intention.
Objective: to describe the results of Heberprot-P® in patients with diabetic foot ulcers in "Raúl Sánchez" Policlinic, Pinar de Río.
Methods: a descriptive, prospective study of 23 patients with the diagnosis of diabetic foot ulcer was conducted from January 2014 to February 2015 in "Raúl Sánchez" Policlinic, Pinar del Río. The patients were applied epidermal growth factor intralesionally. The patients were studied taking into account age, sex, personal-pathological history, severity degree according to Wagner’s classification, the dose and the number of applications, the evaluation of the response and the side effects.
Results: patients aged between 50 and 59 (47, 8 %) predominated in the studied series, as well as female sex (60, 9 %) and diabetes mellitus type II. The greater number of applications was in plantar ulcers degree II. A whole granulation was achieved in the 78, 2 % of the cases and a partial granulation in the 17, 3 %. There was not need of amputations and none of the patients died.
Conclusions: with the use of Heberprot-P®, a favorable evolution has been achieved in most of the cases and the integrity of the limb has been kept as well as its function in most of the patients.


REFERENCES

  1. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Dia-betes Care [Internet]. 2012 Jan [cited 2014 Sep 2];35 Suppl 1:[about 7 p.]. Available from: http://care.diabetesjournals.org/content/35/Supplement_1/S64.extract

  2. Fernández-Montequín JI, Betancourt BY, Leyva-Gonzalez G, Mola EL, Galán-Naranjo K, Ramírez-Navas M, et al. Intralesional ad-ministration of epidermal growth factor-based formulation (Heberprot-P) in chronic diabetic foot ulcer: treatment up to com-plete wound closure. Int Wound J. 2009;6(1):67-72.

  3. Conesa González AJ, Diaz Diaz O, Conesa del Rio JR, Domínguez Alonso JE. Mortalidad por Diabetes mellitus y sus complicaciones. Ciudad de la Habana, 1990-2002. Rev Cub Endocrinol. 2010;21(1):35-50.

  4. Cuba. Ministerio de Salud Pública. Mortali-dad por Diabetes mellitus. Anuario Estadísti-co de Salud 2014. La Habana: Dirección Na-cional de Registros Médicos y Estadísticas de Salud; 2014.

  5. González Fernández RS, Crespo Valdés N, Crespo Mojena N. Características clínicas de la diabetes mellitus en un área de salud. Rev Cubana Med Gen Integr [Internet]. 2000 [citado 12 Mar 2013];16(2):[aprox. 11 p.]. Disponible en: http://bvs.sld.cu/revistas/mgi/vol16_2_00/mgi07200.htm

  6. Meaney B. Diabetic foot care: prevention is better than cure. J Ren Care. 2012;38 Suppl 1:90-8.

  7. Sun JH, Tsai JS. Risk factors for lower ex-tremity amputation in diabetic foot disease categorized by Wagner classification. Diabe-tes Res Clin Pract. 2012;95(3):358-63.

  8. Bekker-Mendez C, Guzman-Aguilar RM. TUNEL-positive cells in the surgical border of an amputation due to infected diabetic foot. Mol Med Report. 2012;5(2):363-72.

  9. Alexiadou K, Doupis J. Management of diabetic foot ulcers. Diabetes Ther. 2012;3(1):4.

  10. Bakker K, Schaper NC. The development of global consensus guidelines on the management and prevention of the dia-betic foot 2011. Diabetes Metab Res Rev. 2012 Feb;28 Suppl 1:116-8.

  11. Balingit PP, Armstrong DG. NorLeu3 -A(1-7) stimulation of diabetic foot ulcer heal-ing: Results of a randomized, parallel-group, double-blind, placebo-controlled phase 2 clinical trial. Wound Repair Regen [Internet]. 2012 [cited 2013 Mar 12];20(4):[about 8 p.]. Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1524-475X.2012.00804.x/full

  12. Bakker KJ. Practical guidelines on the management and prevention of the dia-betic foot 2011. Diabetes Metab Res Rev. 2012;28(Suppl 1):225–31.

  13. Margolis DJ, Malay DS, Hoffstad OJ. Prev-alence of diabetes, diabetic foot ulcer, and lower extremity amputation among Medicare beneficiaries, 2006 to 2008: Da-ta Points#1. Data Points Publication Se-ries [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 [actualizado 17 Feb 2011; citado 12 Mar 2013]. Disponible en: http://www.ncbi.nlm.nih.gov/books/NBK63602/

  14. Marinello Roura J, Blanes Mompó I, Es-cudero Rodríguez JR, Ibáñez Esquembre V, Rodríguez Olay J.

  15. Tratado de Pie Diabético. Barcelona: Cen-tro de Documentación del Grupo Esteve; 2002.

  16. Rivero Fernández F. Experiencias del Pro-grama de atención integral a pacientes con pie diabético en el estado Zulia, Ve-nezuela. Biotecnol Apl [Internet]. Abr-Jun 2010 [citado 12 Mar 2013];27(2):[aprox. 3 p.]. Disponible en: http://scielo.sld.cu/scielo.php?pid=S1027-28522010000200004&script=sci_arttext

  17. Monteiro-Soares M, Boyko J, Ribeiro J, Ribeiro I, Dinis-Ribeiro M. Risk stratifica-tion systems for diabetic foot ulcers: a systematic review. Diabetología. 2011;54:1190–9.

  18. Zaulyanov L, Kirsner RS. A review of a bi-layered living cell treatment (Apligraf) in the treatment of venous leg ulcers and diabetic foot ulcers. Clin Interv Aging. 2007;2(1):93-8.

  19. Alexiadou K, Doupis J. Management of diabetic foot ulcers. Diabetes Ther. 2012;3(1):4.

  20. Bekker-Mendez C, Guzman-Aguilar RM. TUNEL-positive cells in the surgical border of an amputation due to infected diabetic foot. Mol Med Report. 2012;5(2):363-72.

  21. Fernández Montequín J, Gabriela Mena-Violante H, Fernández Santiesteban Ll. Tratamiento y recuperación del pie diabé-tico grado 5 de la clasificación de Wagner tras aplicar el Heberprot-P. Biotecnol Apl [Internet]. 2010 [citado 12 Mar 2013];27(2):[aprox. 3 p.]. Disponible en: Disponi-ble en: http://scieloprueba.sld.cu/scielo.php?script=sci_arttext&pid=S1027-28522010000200005&lng=es&nrm=iso




2020     |     www.medigraphic.com